** Nkarta Inc's NKTX.O slips ~4% in extended trading as co
seeks equity after seeing its stock more than double on Mon
** NKTX surged 140.9% to close at $18.72 after co said
experimental cell therapy treatments showed promise in patients
with different blood disorders urn:newsml:reuters.com:*:nL3N2WN2UV
** Co said the drugs, NKX101 and NKX019, were well
tolerated, with no reports of side effects associated with CAR-T
cell therapies, such as cytokine release syndrome or graft
versus host disease
** After the bell, co launches $150 mln stock offering for
continued clinical development of the drugs urn:newsml:reuters.com:*:nGNXwYHjg
** Cowen, SVB Securities and Evercore jt bookrunners for
offering, which is slated to price overnight/before the bell
Tues
** NKTX has ~33 mln shares outstanding for nearly $620 mln
market cap, per Refinitiv data, and ~29.5 mln of public float
(Lance Tupper is a Reuters market analyst. The views expressed
are his own)
((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-332-219-1430))